Table 4.
Sensitivities and specificities for the PLS-DA classification of Raman spectra from plasma of healthy donors and prostate cancer patients, as well as plasma spectra from patients with different GS.
Patients | Number of LVs | Sensitivity | Specificity |
---|---|---|---|
Healthy donors versus prostate cancer patients | 06 | 89.6% | 90% |
GS 9 versus GS 8 | 07 | 78.7% | 80% |
GS 9 versus GS 7 | 04 | 70% | 75.7% |
GS 8 versus GS 7 | 04 | 63.3% | 66.5% |
GS, Gleason score; PLS-DA, partial least squares discriminant analysis.